JAGX · Jaguar Health, Inc.
$0.79
-0.02 (-2.32%)
At close · Aug 31
Going-concern doubt
— flagged Aug 19, 2026
Substantial doubt about the company's ability to continue as a going concern.
“While management believes this infusion improves our liquidity, it does not fully alleviate the conditions that raise substantial doubt about our ability to continue as a going concern for one year from the issuance of these financial statements.”View the 10-Q filed Aug 19, 2026
Market Cap
$4.19M
Shares
5.17M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$11.51M
-1.5%
FY2025
Net Income
-$53.58M
-39.2%
FY2025
Gross Margin
67.21%
-16.1pp
FY2025
Operating Margin
-398.82%
-135.1pp
FY2025
Diluted EPS
-$803.95
+82.4%
FY2025
Operating Cash Flow
-$23.69M
+19.4%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $27.82M | $11.51M | $11.69M | $9.76M | $11.96M | $4.34M | $9.39M | $5.78M | $4.42M | $4.36M | $141.52K | $258.38K | $0 | |
| $4.92M | $3.77M | $1.96M | $2.04M | $2.02M | $2.33M | $3.28M | $3.82M | $2.77M | $880.41K | $51.97K | $123.46K | — | |
| $22.89M | $7.74M | $9.73M | $7.72M | $9.94M | $2M | $6.11M | $1.96M | $1.65M | $3.48M | $89.56K | $134.92K | — | |
| — | 67.21% | 83.27% | 79.13% | 83.11% | 46.18% | 65.05% | 33.92% | 37.37% | 79.81% | 63.28% | 52.22% | — | |
| $25.24M | $24.97M | $16.54M | $18.6M | $17.65M | $15.08M | $6.41M | $5.82M | $5.15M | $4.27M | $7.21M | $6.48M | $4.22M | |
| $5.18M | $9.24M | $7.69M | $6.46M | $8.84M | $8.89M | $6.61M | $6.94M | $9.83M | $3.08M | $485.44K | $765.09K | — | |
| $17.58M | $18.64M | $16.33M | $16.59M | $17.87M | $17.1M | $14.39M | $13.5M | $12.28M | $11.25M | $5.98M | $5.34M | $4.1M | |
| $1.9M | $1.9M | $1.9M | $2M | $1.8M | $1.7M | $1.7M | $1.7M | $1.69M | $702.78K | — | — | — | |
| $1.9M | $1.91M | $1.9M | $2.01M | $1.98M | $1.72M | $1.73M | $1.74M | $1.32M | $584.34K | $47.49K | $5155 | — | |
| $36.67M | — | — | — | — | — | — | — | $35.24M | $38.61M | $13.73M | $12.7M | $8.32M | |
| $53.71M | $57.42M | $42.52M | $44.05M | $46.37M | $45.04M | $36.03M | $34.72M | $35.24M | — | — | — | — | |
| -$25.9M | -$45.91M | -$30.83M | -$34.29M | -$34.42M | -$40.71M | -$26.65M | -$28.95M | -$30.82M | -$34.25M | -$13.59M | -$12.45M | -$8.32M | |
| — | -398.82% | -263.76% | -351.31% | -287.85% | -939.05% | -283.93% | -501.26% | -697.98% | -785.27% | -9599.84% | -4816.67% | — | |
| -$23.99M | -$44M | -$28.93M | -$32.28M | -$32.43M | -$38.99M | -$24.92M | -$27.21M | -$29.5M | -$33.66M | -$13.54M | -$12.44M | — | |
| $998K | $67K | $231K | $6.38M | $12.72M | $8.42M | $2.79M | $5.73M | $2.63M | $1.21M | $985.55K | $3.32M | $345.34K | |
| $192K | $43K | $51K | $200K | $950K | -$765K | $190K | $81K | $315.69K | $88.55K | -$11.05K | -$27.28K | — | |
| -$123K | -$162K | -$138K | -$51K | — | — | — | — | — | — | — | — | — | |
| -$36.92M | -$54M | -$39.25M | -$41.9M | -$48.4M | -$52.6M | -$33.81M | -$38.53M | -$32.15M | -$35.15M | -$14.73M | — | — | |
| — | $0 | $0 | $0 | $0 | $0 | $0 | $10K | — | -$13.18M | — | — | — | |
| $17.02M | -$53.58M | -$38.49M | -$41.9K | -$48.4K | -$52.6K | -$33.81M | -$38.54M | -$32.15M | -$21.97M | -$14.73M | -$16.29M | -$8.61M | |
| — | -465.42% | -329.3% | -0.43% | -0.4% | -1.21% | -360.25% | -667.34% | -727.92% | -503.73% | -10410.87% | -6305.24% | — | |
| -$524K | -$563K | -$759K | -$601K | -$941K | -$5000 | — | — | — | — | — | — | — | |
| -$52.42M | -$53.58M | -$38.49M | -$41.3M | -$47.45M | -$52.6M | -$38.65M | — | -$32.15M | -$21.97M | -$14.73M | -$16.64M | -$9.26M | |
| -$52.94M | -$53.94M | -$38.31M | -$41.27M | -$48.13M | — | — | — | — | — | — | — | — | |
| USD/shares | $110.14 | -$803.95 | -$4,574.15 | -$93,735.95 | -$1,899,450.00 | -$4,631,550.00 | -$11,812,500.00 | — | — | — | — | — | — |
| USD/shares | $110.14 | -$803.95 | -$4,574.15 | -$93,735.95 | -$1,899,450.00 | -$4,631,550.00 | -$11,812,500.00 | — | — | — | — | — | — |
| shares | — | 66.64K | 8415.2571 | 440.6 | 24.9813 | 11.3553 | 3.2713 | 0.4203 | 0.0178 | 0.2451 | 0.9271 | 0.5209 | 0.2416 |
| shares | — | 66.64K | 8415.2571 | 440.6 | 24.9813 | 11.3553 | 3.2713 | 0.4203 | 0.0178 | 0.2451 | 0.9271 | 0.5209 | 0.2416 |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 2.48×
EV/EBIT
—
P/E (TTM)
—
Peer medians compare against the 126 similar-size Biotechnology companies (of 499 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Human Health Segment | $11,158,000 | $11,374,000 | $9,588,000 | $11,741,000 | $4,273,000 | $9,309,000 |
| Animal Health Segment | $353,000 | $315,000 | $173,000 | $215,000 | $62,000 | $76,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Product | $11,339,000 | $11,560,000 | $9,761,000 | — | $4,335,000 | — |
| Mytesi | $11,000,000 | $11,300,000 | $9,600,000 | $11,700,000 | $4,300,000 | $9,300,000 |
| License | $172,000 | $129,000 | — | — | — | — |
| Canalevia | $148,000 | $160,000 | $130,000 | $167,000 | — | — |
| Neonorm | $35,000 | $28,000 | $42,000 | $48,000 | $62,000 | $76,000 |